Identification of Novel and Pathological Feature of Angiostatic Microvasculature in Liver Metastatic Pancreatic Neuroendocrine Tumors and Its Clinical Implication Abstract #1034

Introduction: Microvasculature of liver metastatic pancreatic neuroendrocrine tumors (LM-PNETs) are unknown.
Aim(s): To visualize in 3D the neoplastic associated neovasculature in LM-PNETs and reveal its novel features.
Materials and methods: An adapted thick human tumor sections immunostaining and 3D construction imaging method was performed.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: ...none of the below
Presenting Author: Xu Han
Authors: Han X, Hexige S, Lou W

To read results and conclusion, please login ...

Further abstracts you may be interested in

#809 Serum Chromogranin A is a Predictor for Liver Metastatic Tumor Burden and Therapeutic Response in Advanced Non-Functional Pancreatic Neuroendocrine Tumors
Introduction: The relationship between CgA level and liver metastatic (LM) tumor burden as well as therapeutic response is not well-established.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: M.D. Xu Han
Authors: Zhang C, Han X, Tang M, Ji Y, ...
Keywords: CgA NF-PNETs LM
#1047 Unresectable Gastrointestinal Neuroendocrine Liver Metastases Treated by Liver-Directed Therapies
Introduction: Hepatic metastases develop in 85% of patients with GI neuroendocrine tumors. Liver-directed therapies allows for manageable microinvasive treatments able to improve the benefit and reduce the toxicity.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Lingxiao J Liu
Authors: Liu L J, Xin B, Ji Y, Yan Z, ...
#1336 Resection of the Primary Tumor Prior to Peptide Receptor Radionuclide Therapy Improves Treatment Response and Progression-free Survival in Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases
Introduction: A low burden of disease represents an independent favorable prognostic factor of response to peptide receptor radionuclide therapy (PRRT) in patients affected by gastro-entero-pancreatic neuroendocrine tumors. However it is not clear whether this is due to a lower diffusion of the disease or thanks to debulking surgery
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Surgical treatment
Presenting Author: MD Emilio Bertani
Authors: Bertani E, Fazio N, Grana C, Bodei L, ...
#321 Role of VEGFR-2, P53, P53R2 and Ki-67 Expression in Metastatic Carcinoid Cancer
Introduction: Ki-67 expression is a well-known prognostic factor in neuroendocrine tumors. The role of modified expression of p53, p53R2 and VEGFR2 in this disease’s liver metastases has not been established.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Ranyell Matheus Spencer
Authors: Spencer R, Costa W, Salvador H, Diniz A, ...
#437 mTOR Expression in Primary Pancreatic Neuroendocrine Tumors and their Metastases
Introduction: The mammalian target of rapamycin (mTOR), an important regulator of cell proliferation and invasion, is activated in pancreatic neuroendocrine tumors (PNETs). Information on detailed expression of mTOR in locally advanced or metastatic PNET is poorly described.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Vera Delektorskaya
Authors: Kozlov N, Pavlovskaya A, ...